Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China-Reference-Cited by-同舟云学术

Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China

Published:2020-04-29 Issue:7 Volume:16 Page:1691-1698
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Hu Yuemei¹,Shao Ming²,Hu Yuansheng³,Liang Qi¹,Jia Ningning³,Chu Kai¹,Xu Li⁴,Li Jing⁴,Li Changgui²,Zhu Fengcai¹

Affiliation:

1. Clinical Trials Assessment Department, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China

2. Division of Respiratory Virus Vaccines, National Institutes for Food and Drug Control, Beijing, China

3. Clinical Research Department, Sinovac Biotech Co., LTD., Beijing, China

4. Quality Assurance Department, Sinovac Biotech Co., LTD., Beijing, China

Funder

Sinovac Biotech Co., LTD

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1721994

Reference30 articles.

1. Literature review of the epidemiology of influenza B disease in 15 countries in the Asia-Pacific region

2. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices—United States, 2018–19 Influenza Season

3. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Self-Assembling Nanoparticle Hemagglutinin Influenza Vaccines Induce High Antibody Response;International Journal of Molecular Sciences;2024-07-01

2. Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: an overview of systematic reviews;BMC Infectious Diseases;2023-08-29

3. Immunogenicity and safety of quadrivalent inactivated influenza vaccine in children aged 6 to 35 months: A systematic review and meta-analysis;Human Vaccines & Immunotherapeutics;2023-08

4. A Comparison of Etiology, Pathogenesis, Vaccinal and Antiviral Drug Development between Influenza and COVID-19;International Journal of Molecular Sciences;2023-03-28

5. Immunogenicity and safety of seasonal influenza vaccines in children under 3 years of age;Expert Review of Vaccines;2023-03